First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose

Glioblastoma is the most common primary brain malignancy with limited treatment options. EphA2 is a tumor-associated-antigen overexpressed in glioblastoma. Pre-clinical studies have demonstrated the promise of EphA2-redirected CAR T-cells against glioblastoma. We conduct the first-in-human trial of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Qingtang, Ba, Teer, Ho, Jinyuan, Chen, Dandan, Cheng, Ye, Wang, Leiming, Xu, Geng, Xu, Lixin, Zhou, Yiqiang, Wei, Yukui, Li, Jianqiang, Ling, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256846/
https://www.ncbi.nlm.nih.gov/pubmed/34235085
http://dx.doi.org/10.3389/fonc.2021.694941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256846/
https://www.ncbi.nlm.nih.gov/pubmed/34235085
http://dx.doi.org/10.3389/fonc.2021.694941

Ejemplares similares